Catalogue Number
BD-D1326
Analysis Method
HPLC,NMR,MS
Specification
98%(HPLC)
Storage
2-8℃
Molecular Weight
222.37
Appearance
Colorless liquid
Botanical Source
Eriobotrya japonica Thunb./A component of many essential oils
Structure Type
Sesquiterpenoids
Category
Standards;Natural Pytochemical;API
SMILES
CC(=CCCC(=CCCC(C)(C=C)O)C)C
Synonyms
HuMbertiol/1,6,10-Dodecatrien-3-ol, 3,7,11-trimethyl-/Nerolidol/3,7,11-Trimethyl-1,6,10-dodecatrien-3-ol/cis/trans-Nerolidol/3,7,11-trimethyldodeca-1,6,10-trien-3-ol/FCI-119b/trans,cis-nerblidol/TRANS-NEROLIDOL/NEROLIDOL,TRANS
IUPAC Name
(6E)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol
Density
0.9±0.1 g/cm3
Solubility
Flash Point
96.1±0.0 °C
Boiling Point
276.0±0.0 °C at 760 mmHg
Melting Point
-75 °C
InChl
InChl Key
WGK Germany
RID/ADR
HS Code Reference
2905220000
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:7212-44-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
29210667
BACKGROUND:
Research on natural bioactive compounds has increased exponentially over the last decades. The discovery of new phytochemicals that possess pharmaceutical properties is useful in the development of therapeutic alternatives. The nerolidol (3,7,11-trimetil-1,6,10-dodecatrien-3-ol or 3,7,11-trimetildodeca-1,6,10-trien-3-ol) has been extensively studied for its therapeutic potential because of its pharmacological activities in the treatment of neurodegenerative diseases.
METHOD:
All articles and patents regarding nerolidol and its pharmacological properties were revised, focusing mainly on the important properties in the treatment of neurodegenerative diseases. A thorough search in article databases (Science Direct, MEDLINE/PubMed, Scopus and Scielo) and patent database (WIPO, EPO, ESPTO, LATIPAT and INPI) was performed over the course of this study.
RESULTS:
Several studies stood out for their relevance regarding the treatment of neurodegenerative diseases. Nerolidol demonstrated anticholinesterasic, antioxidant, antinociceptive, anti-inflammatory and anxiolytic activities, thus classifying it as a promising phytochemical for the development of therapeutic drugs.
CONCLUSION:
Analysis suggested that nerolidol is a promising target for new drugs and treatment of neurodegenerative diseases.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Alzheimer`s; Nerolidol; epilepsy; neurodegenerative diseases; pharmacological application; sesquiterpene.
Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review.
De Carvalho RBF1, De Almeida AAC1, Campelo NB2, Lellis DROD2, Nunes LCC1,2.
2018
27136520
Nerolidol (3,7,11-trimethyl-1,6,10-dodecatrien-3-ol) is a naturally occurring sesquiterpene alcohol that is present in various plants with a floral odor. It is synthesized as an intermediate in the production of (3E)-4,8-dimethy-1,3,7-nonatriene (DMNT), a herbivore-induced volatile that protects plants from herbivore damage. Chemically, nerolidol exists in two geometric isomers, a trans and a cis form. The usage of nerolidol is widespread across different industries. It has been widely used in cosmetics (e.g., shampoos and perfumes) and in non-cosmetic products (e.g., detergents and cleansers). In fact, U.S. Food and Drug Administration (FDA) has also permitted the use of nerolidol as a food flavoring agent. The fact that nerolidol is a common ingredient in many products has attracted researchers to explore more medicinal properties of nerolidol that may exert beneficial effect on human health. Therefore, the aim of this review is to compile and consolidate the data on the various pharmacological and biological activities displayed by nerolidol. Furthermore, this review also includes pharmacokinetic and toxicological studies of nerolidol. In summary, the various pharmacological and biological activities demonstrated in this review highlight the prospects of nerolidol as a promising chemical or drug candidate in the field of agriculture and medicine.
cis-nerolidol; essential oil; pharmacological activities; sesquiterpene; trans-nerolidol
Nerolidol: A Sesquiterpene Alcohol with Multi-Faceted Pharmacological and Biological Activities.
Chan WK1,2, Tan LT3,4, Chan KG5, Lee LH6,7,8, Goh BH9,10,11.
2016 Apr 28
28093813
Acute kidney injury (AKI) is a critical care syndrome, resulting in acute reduction of renal function and up to 22% mortality of hospitalized patients. Nerolidol is a major component in several essential oils that possesses various pharmacological properties. The present study aimed to investigate the potential effect of nerolidol on lipopolysaccharide (LPS)-induced AKI. Nerolidol dose-dependently reduced the pathological injuries of kidney induced by LPS in rats. Nerolidol significantly decreased the levels of blood urea nitrogen and creatinine in LPS-treated rats in a dose-dependent manner. In addition, nerolidol inhibited LPS-induced decrease of cell viability in NRK-52E rat proximal tubular cells, which effect was concentration dependent. Nerolidol notably inhibited the increase of TNFα and IL-1β in LPS-treated rats and the mRNA expression of TNFα and IL-1β in LPS-treated NRK-52E cells. Nerolidol suppressed the increase of toll-like receptor 4 (TLR4) expression, phosphorylation and nuclear translocation of p65 NF-κB in kidneys of LPS-treated rats and LPS-treated NRK-52E cells. Overexpression of TLR4 and p65 NF-κB significantly suppressed nerolidol-induced inhibition of TNFα and IL-1β expression and increase of cell viability in LPS-treated cells. In summary, we found that nerolidol played a critical anti-inflammatory effects through inhibition of TLR4/NF-κB signaling and protected against LPS-induced AKI.
Copyright © 2017 John Wiley & Sons, Ltd.
NF-κB; acute kidney injury; lipopolysaccharide; nerolidol; toll-like receptor 4
Nerolidol Protects Against LPS-induced Acute Kidney Injury via Inhibiting TLR4/NF-κB Signaling.
Zhang L1, Sun D1, Bao Y1, Shi Y1, Cui Y1, Guo M2.
2017 Mar
